• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 4:23:40 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $VNRX alert in real time by email
    SC 13G 1 volitionrx_13gdec312020.htm INITIAL FILING

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. ___)*

     

     

    VolitionRX Ltd

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    928661107

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

     

    [X] Rule 13d-1(b)

    [   ] Rule 13d-1(c)

    [   ] Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

     


    CUSIP NO.  928661107
    (1) Names of Reporting Persons.  I.R.S. Identification Nos. of Above Persons (entities only):  

     

    Lagoda Investment Management, L.P.  

    46-4740139

     
    (2) Check the Appropriate Box if a Member of a Group (a) [   ]  
      (b) [   ]  
         
    (3) SEC Use Only
    (4) Citizenship or Place of Organization
      Delaware  
    Number of Shares Beneficially Owned By Each Reporting Person With
      (5) Sole Voting Power: 2,547,481*  
      (6) Shared Voting Power: 0*  
      (7) Sole Dispositive Power: 2,547,481*  
      (8) Shared Dispositive Power: 0*  
           
    (9) Aggregate Amount Beneficially Owned by Each Reporting Person:    2,547,481
         

    (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):

    [   ]

    (11) Percent of Class Represented by Amount in Row (9):    5.3%*
    (12) Type of Reporting Person (See Instructions):   IA
                 

    * Lagoda Investment Management, L.P. (the “Reporting Person”) serves as the investment manager to certain managed accounts (the “Accounts”) and possesses the sole power to vote and the sole power to direct the disposition of all securities of VolitionRX Ltd (the “Issuer”) held by the Accounts. The general partner of the Reporting Person is Lagoda Investment Management, LLC, a Delaware limited liability company (the “General Partner”). Fatima Dickey, as the sole member of the General Partner, possesses the voting and dispositive power with respect to all securities beneficially owned by the Reporting Person.

     

    As of December 31, 2020, the Accounts held 2,547,481 shares of common stock of the Issuer, par value $0.001 per share (the “shares”).

     

    Based on information disclosed in the Issuer’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2020, filed with the Securities and Exchange Commission on November 12, 2020, there were 48,197,687 shares outstanding as of November 4, 2020. As a result of the foregoing, for purposes of Reg. Section 240.13d-3, the Reporting Person beneficially owns 2,547,481 shares, or 5.3% of the shares deemed issued and outstanding as of December 31, 2020.

     
     

     

    Item 1(a).  Name Of Issuer:
     

    VolitionRX Ltd

     

    Item 1(b).  Address of Issuer’s Principal Executive Offices:
     

    13215 Bee Cave Parkway

    Suite 125, Galleria Oaks B

    Austin, Texas 78738

    Item 2(a).  Name of Person Filing:
     

    This report on Schedule 13G (this “Schedule 13G”) is being filed by Lagoda Investment Management, L.P. (the “Reporting Person”). The Reporting Person serves as the investment manager to certain managed accounts (the “Accounts”), and possesses the sole power to vote and the sole power to direct the disposition of all securities of VolitionRX Ltd held by the Accounts. The general partner of the Reporting Person is Lagoda Investment Management, LLC, a Delaware limited liability company. Fatima Dickey, as the sole member of the general partner of Lagoda Investment Management, possesses the voting and dispositive power with respect to all securities beneficially owned by the Reporting Person.

     

    As of December 31, 2020, the Accounts held 2,547,481 shares of common stock of the Issuer, par value $0.001 per share.

     

    Based on information disclosed in the Issuer’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2020, filed with the Securities and Exchange Commission on November 12, 2020, there were 48,197,687 shares outstanding as of November 4, 2020. As a result of the foregoing, for purposes of Reg. Section 240.13d-3, the Reporting Person owns 2,547,481 shares, or 5.3% of the shares deemed issued and outstanding as of December 31, 2020.

    Item 2(b).  Address of Principal Business Office or, if None, Residence:
     

    The address for the Reporting Person is:

    3 Columbus Circle, New York, NY 10019

    Item 2(c).  Citizenship:
      Lagoda Investment Management, L.P. is organized under the laws of the State of Delaware.
    Item 2(d).  Title of Class of Securities:
      Common Stock, $0.001 par value per share.
     
     

     

    Item 2(e).  CUSIP No.:
      928661107
    Item 3.  If This Statement Is Filed Pursuant to §§240.13d-1(b) or 13d-2(b) or (c), check whether the Person Filing is a:  
      (a) [   ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);  
      (b) [   ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);  
      (c) [   ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);  
      (d) [   ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);  
      (e) [X] An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);  
      (f) [   ] An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);  
      (g) [   ] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);  
      (h) [   ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);  
      (i) [   ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);  
      (j) [   ] Group, in accordance with §240.13d-1(b)(1)(ii)(J).  
           
     
     

     

    Item 4.  Ownership:
    As reported in the cover pages to this report, the ownership information with respect to the Reporting Person is as follows:
      (a)  Amount Beneficially Owned: 2,547,481*  
      (b)  Percent of Class: 5.3%*  
         (c)  Number of Shares as to which such person has:    
             

           
      (i)  Sole power to vote or to direct the vote: 2,547,481*  
      (ii)  Shared power to vote or to direct the vote: 0*  
      (iii)  Sole power to dispose or to direct the disposition of: 2,547,481*  
      (iv)  Shared power to dispose or to direct the disposition of: 0*  
           

    __________________

    * Reporting Person serves as the investment manager to the Accounts and possesses the sole power to vote and the sole power to direct the disposition of all securities of the Issuer held by the Accounts. Fatima Dickey, as the sole member of the General Partner, possesses the voting and dispositive power with respect to all securities beneficially owned by the Reporting Person.

     

    As of December 31, 2020, the Accounts held 2,547,481 shares.

     

    Based on information disclosed in the Issuer’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2020, filed with the Securities and Exchange Commission on November 12, 2020, there were 48,197,687 shares outstanding as of November 4, 2020. As a result of the foregoing, for purposes of Reg. Section 240.13d-3, the Reporting Person beneficially owns 2,547,481 shares, or 5.3% of the shares deemed issued and outstanding as of December 31, 2020. 

     

    Item 5.  Ownership of Five Percent or Less of a Class:
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [  ]
    Item 6.  Ownership of More Than Five Percent on Behalf of Another Person:
      Not Applicable.
     
     

     

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
      Not Applicable.
    Item 8.  Identification and Classification of Members of the Group:
      Not Applicable.
    Item 9.  Notice of Dissolution of Group:
      Not Applicable.
    Item 10.  Certification:
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

      February 16, 2021  
         
      LAGODA INVESTMENT MANAGEMENT, L.P.  
         
         
      By: /s/ Jason A. Ozone  
        Name:  Jason A. Ozone  
        Title:  Chief Financial Officer & Chief of Compliance Officer  
         
         

     

     

     

    Attention: Intentional misstatements or omissions of fact constitute
    Federal criminal violations (See 18 U.S.C. 1001).

     

    Get the next $VNRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VNRX

    DatePrice TargetRatingAnalyst
    4/8/2025$2.50Buy
    H.C. Wainwright
    2/1/2023Buy → Hold
    The Benchmark Company
    2/17/2022$8.00 → $7.00Overweight
    Cantor Fitzgerald
    11/16/2021$10.00 → $9.00Buy
    Aegis Capital
    More analyst ratings

    $VNRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on VolitionRx with a new price target

    H.C. Wainwright initiated coverage of VolitionRx with a rating of Buy and set a new price target of $2.50

    4/8/25 8:02:28 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx downgraded by The Benchmark Company

    The Benchmark Company downgraded VolitionRx from Buy to Hold

    2/1/23 7:40:33 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Cantor Fitzgerald resumed coverage on VolitionRx with a new price target

    Cantor Fitzgerald resumed coverage of VolitionRx with a rating of Overweight and set a new price target of $7.00 from $8.00 previously

    2/17/22 9:10:02 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs

    HENDERSON, Nev., Oct. 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), and its subsidiary, Volition Veterinary Diagnostics Development LLC, in line with their corporate social responsibility strategy announces participation at the HOPE Animal-Assisted Crisis Response Dogs (HOPE AACR) Annual Conference in Virginia Beach. Volition donated its Nu.Q® Vet Cancer Test to support dogs that provide emotional comfort and support to people affected by crises and disasters across the United States.   Dr. Michelle Silver, DVM, DACVIM – Oncology, commented: "Ensuring our crisis canines are healthy is our number one priority. Throughout my career in veteri

    10/17/25 8:00:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants

    HENDERSON, Nev., Oct. 10, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an underwritten public offering of 11,550,000 shares of its common stock and warrants to purchase up to 11,550,000 shares of its common stock. The public offering price of for each share of common stock and an accompanying warrant to purchase one share of common stock is $0.52 per set of securities (with $0.01 allocated to the warrant). Each warrant has an exercise price per share of $0.60, is exercisable immediately upon issuance, and expires five years from the issuance date. In connection with the offering, Volit

    10/10/25 8:30:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants

    HENDERSON, Nev., Oct. 9, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it is proposing to offer and sell, in an underwritten public offering, shares of its common stock and accompanying common stock purchase warrants. In addition, Volition intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock and warrants offered in the offering at the public offering price, less underwriting discounts and commissions. All of the securities in the offering are being offered by Volition. The final terms of the proposed offering will depend on ma

    10/9/25 4:05:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Reynolds Cameron John bought $56,100 worth of shares (110,000 units at $0.51), increasing direct ownership by 5% to 2,534,847 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    10/15/25 4:05:45 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Innes Guy Archibald bought $49,038 worth of shares (96,153 units at $0.51), increasing direct ownership by 10% to 1,062,967 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    10/15/25 4:05:33 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Still Timothy I bought $24,519 worth of shares (48,076 units at $0.51), increasing direct ownership by 3% to 1,535,458 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    10/15/25 4:05:10 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    SEC Filings

    View All

    VolitionRX Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - VOLITIONRX LTD (0000093314) (Filer)

    10/14/25 5:12:48 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 424B5 filed by VolitionRX Limited

    424B5 - VOLITIONRX LTD (0000093314) (Filer)

    10/14/25 9:22:04 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 424B5 filed by VolitionRX Limited

    424B5 - VOLITIONRX LTD (0000093314) (Filer)

    10/9/25 4:08:13 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Reynolds Cameron John bought $56,100 worth of shares (110,000 units at $0.51), increasing direct ownership by 5% to 2,534,847 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    10/15/25 4:05:45 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Innes Guy Archibald bought $49,038 worth of shares (96,153 units at $0.51), increasing direct ownership by 10% to 1,062,967 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    10/15/25 4:05:33 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Still Timothy I bought $24,519 worth of shares (48,076 units at $0.51), increasing direct ownership by 3% to 1,535,458 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    10/15/25 4:05:10 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Leadership Updates

    Live Leadership Updates

    View All

    Volition Issues Business Review 2024

    HENDERSON, Nev., Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year. Volition's major achievements in 2024 include: Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 20 countries worldwide.Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024.Hosted Satellite Symposium at European Society of Intensive Care Medicine 2024 showcasing Nu.Q® NETs clinical utility in over 3,000 intensive care sepsis patients.Continued to strengthen our strategic patent portfolio.Made significant progress a

    1/8/25 8:30:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Volition Appoints Timothy I. Still as Chairman

    HENDERSON, Nev., Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with REVIVAL Healthcare. An accomplished executive with a career spanning over 35 years in medical diagnostics, devices and digital health, his background includes extensive experience in designing and implementing highly focused commercial and business development

    11/6/24 4:10:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Volition Appoints Dr. Ethel Rubin as an Independent Director

    HENDERSON, Nev., Sept. 30, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr. Ethel Rubin to its board of directors, as an independent director, effective September 30, 2024. Dr. Rubin has also been appointed as a member of the Audit Committee and the Compensation Committee. Dr. Rubin has over 20 years' experience within the life sciences sector, leading healthcare innovation and commercialization strategies for a wide range of organizations – from early-stage operations to large global corporate businesses

    9/30/24 4:10:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Financials

    Live finance-specific insights

    View All

    VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

    Conference call to take place on Friday, August 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev., Aug. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, August 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the second quarter of 2025 and to provide a business update. Details of this event can be found below. Event:   VolitionRx Limited Second Quarter 2025 Earnings and Business Update Conference Call Date:     Friday, August 15, 2025Time:    8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 34

    8/8/25 8:30:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

    Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., May 15, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter ended March 31, 2025.  Volition management will host a conference call tomorrow, May 16 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said: "2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q® platform in the hum

    5/15/25 5:37:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

    Conference call to take place on Friday, May 16 at 8:30 a.m. U.S Eastern Time Henderson, Nev., May 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, May 16 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the first quarter of 2025 and to provide a business update. Details of this event can be found below. Event:   VolitionRx Limited First Quarter 2025 Earnings and Business Update Conference CallDate:     Friday, May 16, 2025 Time:    8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll fr

    5/12/25 8:30:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by VolitionRX Limited

    SC 13G - VOLITIONRX LTD (0000093314) (Subject)

    11/14/24 4:05:14 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by VolitionRX Limited

    SC 13G - VOLITIONRX LTD (0000093314) (Subject)

    11/14/24 3:40:04 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by VolitionRX Limited (Amendment)

    SC 13G/A - VOLITIONRX LTD (0000093314) (Subject)

    2/14/24 4:05:45 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care